NCT05481177View on ClinicalTrials.gov

Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort

PHASE4RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
Long Haul COVIDPostural Orthostatic Tachycardia Syndrome
Interventions
DRUG

Ivabradine

Ivabradine is a drug approved to treat tachycardia in volunteers with heart failure. This study is to determine benefit of ivabradine treatment in postural orthostatic tachycardia syndrome (POTS) in participants with Long haul Covid.

Trial Locations (1)

20814

RECRUITING

Uniformed Services University, Bethesda

All Listed Sponsors
lead

Uniformed Services University of the Health Sciences

FED